Using network pharmacology to discover potential drugs for hypertrophic scars
British Journal of Dermatology · 18.09.2024 · 191 (4) · 592-604
DOI: 10.1093/bjd/ljae234 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 31.05.2024. Verfasst von Yi Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Research Center of Plastic Surgery Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, P.R. China. Hauptthemen laut MEDLINE: Cicatrix, Hypertrophic, Fibroblasts, Molecular Docking Simulation, Cell Proliferation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: Medical and Health Innovation Project of the Chinese Academy of Medical Sciences, Central Research Institute Fund of the Chinese Academy of Medical Sciences.
Abstract (Originalsprache)
Background
Hypertrophic scarring is a disease of abnormal skin fibrosis caused by excessive fibroblast proliferation. Existing drugs have not achieved satisfactory therapeutic effects.
Objectives
To explore the molecular pathogenesis of hypertrophic scars and screen effective drugs for their treatment.
Methods
Existing human hypertrophic scar RNA sequencing data were utilized to search for hypertrophic scar-related gene modules and key genes through weighted gene co-expression network analysis (WGCNA). Candidate compounds were screened in a compound library. Potential drugs were screened by molecular docking and verified in human hypertrophic scar fibroblasts and a mouse mechanical force hypertrophic scar model.
Results
WGCNA showed that hypertrophic scar-associated gene modules influence focal adhesion, the transforming growth factor (TGF)-β signalling pathway and other biologic pathways. Integrin β1 (ITGB1) is the hub protein. Among the candidate compounds obtained by computer virtual screening and molecular docking, crizotinib, sorafenib and SU11274 can inhibit the proliferation and migration of human hypertrophic scar fibroblasts and profibrotic gene expression. Crizotinib had the best effect on hypertrophic scar attenuation in mouse models. At the same time, mouse ITGB1 small interfering RNA can also inhibit mouse scar hyperplasia.
Conclusions
ITGB1 and TGF-β signalling pathways are important for hypertrophic scar formation. Crizotinib could be a potential treatment drug for hypertrophic scars.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Research Center of Plastic Surgery Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, P.R. China.
- Key Laboratory of External Tissue and Organ Regeneration, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P.R. China.
- Department of Plastic Surgery, Plastic Surgery Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, P.R. China.
ORCID-Profile: Zhigang Yang, Ran Xiao
Förderung
- Medical and Health Innovation Project of the Chinese Academy of Medical Sciences
- Central Research Institute Fund of the Chinese Academy of Medical Sciences
Zitieren
APA
Zhang, Y., Li, X., Yu, Q., Lv, X., Li, C., Wang, L., Liu, Y., Wang, Q., Yang, Z., Fu, X., & Xiao, R. (2024). Using network pharmacology to discover potential drugs for hypertrophic scars. British Journal of Dermatology, 191(4), 592-604. https://doi.org/10.1093/bjd/ljae234
Vancouver
Zhang Y, Li X, Yu Q, Lv X, Li C, Wang L, et al. Using network pharmacology to discover potential drugs for hypertrophic scars. British Journal of Dermatology. 2024;191(4):592-604. doi:10.1093/bjd/ljae234
BibTeX
@article{Zhang2024,
author = {Zhang, Yi and Li, Xiu and Yu, Qian and Lv, Xiaoyan and Li, Chen and Wang, Lianzhao and Liu, Yue and Wang, Qian and Yang, Zhigang and Fu, Xin and Xiao, Ran},
title = {Using network pharmacology to discover potential drugs for hypertrophic scars},
journal = {British Journal of Dermatology},
year = {2024},
volume = {191},
number = {4},
pages = {592--604},
doi = {10.1093/bjd/ljae234}
}
EUVIMED